Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
When Context Changes What a Drug Result Means
2026-10-15
A reported inhibition result is inseparable from its model, comparator, readout, and evidence provenance. The contrast between GDC-0941 product descriptions and Gu et al.’s pancreatic cancer study illustrates why pathway suppression, reduced proliferation, and altered invasion should not be treated as interchangeable findings.
EPZ-6438 in HPV-Associated Cervical Cancer
2026-10-14
Published evidence supports EPZ-6438 as a biologically active EZH2 inhibitor in cervical cancer cell models, with reported effects on proliferation, apoptosis, cell-cycle distribution, viral oncoprotein expression, and epithelial-state markers. However, the comparison with cisplatin and the preliminary chorioallantoic membrane findings do not yet establish target-specific action, superior therapeutic benefit, or clinical relevance.
Mc-Val-Cit-PABC-PNP: Evidence and Scope
2026-10-14
Mc-Val-Cit-PABC-PNP is cataloged by APExBIO as a cathepsin-cleavable ADC peptide linker for research involving lysosome-associated payload release. The available evidence is limited to supplier documentation: no matched paper, independent validation, comparative study, or outcome statistics were provided.
BNNC and Hypoxia-Activated Cyclin K Degradation
2026-10-13
A source-grounded overview of BNNC, a hypoxia-responsive photomolecular glue designed to combine Cyclin K degradation with phototherapy, emphasizing the study’s preclinical findings, evidentiary limits, and the distinction between reported apoptosis biology and mitochondrial membrane-potential assays.
DDX3X, Ferroptosis and KRAS-Driven Lung Cancer
2026-10-13
The cited 2025 study asks whether DDX3X sustains KRAS-driven lung cancer by preserving cysteine and glutathione metabolism, and whether disrupting this axis can promote ferroptotic tumor suppression. Its findings support a DDX3X–JUND–METTL16–CBS regulatory model and provide preclinical evidence for DDX3X degradation, while leaving important questions about clinical relevance, model generalizability and long-term safety unresolved.
Multiplexed CRISPR: What Evidence Shows
2026-10-12
A 2025 review describes the potential and risks of multiplexed CRISPR–Cas editing, but it does not provide product-specific evidence for three ANGPTL3-targeting guide RNAs. The main evidence gaps concern direct comparisons, structural-variant measurement, cellular effects, and applicability to specific human-cell contexts.
Pregnenolone Carbonitrile: Context and Limits
2026-10-12
A 2025 mouse study reports that Pregnenolone-16α-carbonitrile reduced phenytoin-associated hippocampal injury while producing tissue-specific changes in cytochrome P450 expression. The findings support further investigation of brain–liver differences in nuclear-receptor signaling, but they do not establish a human treatment strategy or validate broader antifibrotic and detoxification claims.
Quercetin, Hippo Signaling, and Cataract Protection
2026-10-10
A 2025 study combines network pharmacology, a UVB-induced cataract mouse model, and injured lens epithelial cells to examine how quercetin may protect the lens through Hippo-pathway modulation. The findings connect reduced oxidative stress with improved epithelial survival and proliferation, while pathway reactivation partially reverses these effects; however, the evidence remains preclinical and mechanistic rather than clinically confirmatory.
Live-Dead Cell Staining Kit: Product Overview
2026-10-09
The APExBIO Live-Dead Cell Staining Kit (SKU K2081) is described as a dual-fluorescent Calcein-AM Propidium Iodide staining product for distinguishing cells with intact versus compromised membranes. No matched research paper was provided, so independent performance, validation, and comparative claims cannot be established.
Veratridine and the Logic of Excitotoxicity
2026-10-09
Veratridine is a voltage-gated sodium channel opener that connects channel inactivation, depolarization, calcium dysregulation, and neuronal injury. This evidence-focused analysis explains what veratridine models can show, what they cannot establish, and why a classic o-agatoxin IVA study remains important for excitotoxicity research.
Quercetin, Hippo Signaling, and Cataract Protection
2026-10-08
A 2025 study links quercetin’s protective effects in cataract models to suppression of Hippo pathway activity, reduced oxidative stress, and improved lens epithelial-cell survival. The evidence is mechanistically suggestive but remains limited to network analysis, mouse models, and injured cell cultures, so its clinical relevance requires further validation.
Veratridine: From Channel Gating to Translation
2026-10-08
A source-grounded perspective on Veratridine as a voltage-gated sodium channel opener, integrating sodium channel dynamics research, excitotoxicity studies, assay strategy, translational limits, and future opportunities.
Locally Produced DENV-1 RT-LAMP: Study Insights
2026-10-07
The 2025 reference study presents a modular recombinant enzyme system and a DENV-1 primer design intended to reduce dependence on imported diagnostic ingredients in resource-limited settings. Its reported analytical evidence includes detection at 10 copies and discrimination of positive and negative reactions through turbidity, but the work remains pre-clinical and does not establish clinical diagnostic performance.
Glabridin–Gold(I) Complex and Antitumor Immunity
2026-10-07
The reference study introduces complex 6d, which combines an N-heterocyclic carbene gold(I) center with glabridin to target both thioredoxin reductase and MAPK-related immunosuppressive signaling. In liver cancer models, the authors report enhanced dendritic-cell maturation, reduced suppressive immune-cell populations, lower PD-L1 expression, and increased granzyme B, while emphasizing that further validation is needed before clinical translation.
BH3-Mimetics and Apoptotic Sensitivity in Glioblastoma
2026-10-06
Koessinger and colleagues found that glioblastoma, including stem-like tumor cells, depends on the anti-apoptotic proteins BCL-xL and MCL-1 and displays increased apoptotic priming. Their study supports a context-dependent strategy in which combined targeting of these survival dependencies produces antitumor activity in preclinical models, while also highlighting the limits of translating findings from GBM models to clinical treatment.